Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9515010.26442/20751753.2018.12.180108ArticlesСтатьиResearch ArticleDifferentsial'naya diagnostika osteoartrita i podagry: osnovnye podkhody k terapiiДифференциальная диагностика остеоартрита и подагры: основные подходы к терапииPogozhevaE. YuПогожеваЕлена Юрьевна

канд. мед. наук, науч. сотр

lifequality@yandex.ruAmirdzhanovaV. NАмирджановаВера Николаевна

д-р мед. наук, вед. науч. сотр.

KarateevA. EКаратеевАндрей Евгеньевич

д-р мед. наук, рук. лаб. патофизиологии боли и полиморфизма скелетно-мышечных заболеваний

aekarat@yandex.ruV.A.Nasonova Research Institute of RheumatologyФГБНУ «Научно-исследовательский институт ревматологии им. В.А.Насоновой»151220182012VOL 20, NO12 (2018)ТОМ 20, №12 (2018)12212528122021Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95150

The article presents differential diagnosis of osteoarthritis and gout, aspects of clinical presentation, laboratory and instrumental studies results. Algorithm on osteoarthritis management and renewed European League Against Rheumatism (EULAR) guidelines on gout treatment are presented. Aims and main principles of gout and osteoarthritis therapy are discussed. Data on mechanism of action, characteristics, clinical effectiveness and safety of diacerein (interleukine-1 inhibitor) are presented. Results of clinical studies of febuxostat (selective inhibitor of xanthinoxidase) are presented, its effectiveness in uric acid level control, possibilities of use in patients with chronic kidney disease, non-responsive or allergic to allopurinol therapy, are shown

В статье представлены дифференциальная диагностика подагры и остеоартрита, особенности клинической картины, данных лабораторного, инструментального обследования. Продемонстрированы алгоритм ведения пациентов с остеоартритом и обновленные рекомендации Европейской лиги против ревматизма (European League Against Rheumatism, EULAR) по лечению подагры. Обсуждаются цели и основные принципы терапии подагры и остеоартрита. Представлены данные об особенностях механизма действия, клинической эффективности и безопасности диацереина (ингибитор интерлейкина-1). Приведены данные клинических исследований препарата фебуксостат (селективный ингибитор ксантиноксидазы), показаны его эффективность в отношении контроля уровня мочевой кислоты, возможность назначения пациентам с хронической почечной недостаточностью, резистентностью к терапии аллопуринолом и аллергическими реакциями на него.

osteoarthritisgoutdifferential diagnosiseffectiveness and safetydiacereinfebuxostatостеоартритподаградифференциальная диагностикаэффективность и безопасностьдиацереинфебуксостатРевматология. Клинические рекомендации. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017; с. 240-65.Насонов Е.Л. Ревматология. Клинические рекомендации. М.: ГЭОТАР, 2005; с. 264.Jordan K.M, Arden N.K, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.Zhang W, Nuki G, Moskowitz R.W et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.Bruyère O, Cooper C, Pelletier J-P et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally. A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; 44 (3): 253-63.Министерство здравоохранения Российской Федерации. Клинические рекомендации. Остеоартроз. 2016. IDКР256.Pelletier J, Yaron M, Haraoui B et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43 (10): 2339-48.Pavelka K, Trc T, Karpas K et al. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee. Arthritis Rheum 2007; 56 (12): 4055-64.Louthrenoo W, Nilganuwong S, Aksaranugraha S et al. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage 2007; 15 (6): 605-14.Zheng W, Tang F, Li J et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J 2006; 21 (2): 75-80.Sharma A, Rathod R, Baliga V.P. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteoarthritis of the knee (DOK). J Indian Med Assoc 2008; 106 (1): 54-6, 58.Dougados M, Nguyen M, Berdah L et al. ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in oa of the hip. Arthritis Rheum 2001; 44 (11): 2539-47.Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014.Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42.Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 2014; 37 (10): 919-25.Whelton A, MacDonald P.A, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 2013; 125 (1): 106-14.Becker M.A, Schumacher H.R, Wortmann R.L et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353 (23): 2450-61.Schumacher H.R, Becker M.A, Wortmann R.L et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59 (11): 1540-8.Wortmann R.L, Becker M.A, Schumacher H.R et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial. ACR/ARHP Annual Scientific Meeting, 2006.Becker M.A, Schumacher H.R, Espinoza L.R et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12 (2): R63.Schumacher H.R, Becker M.A, Wortmann R.L et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, openlabel extension study [abstract no. OP0130]. Ann Rheum Dis 2006; 65 (Suppl. II): 93.